Dynavax Technologies Corp.

+0.16 (+1.66%)
7:59:44 PM EDT: $9.85 +0.04 (+0.41%)
Products, Regulatory, Earnings Announcements

Clover Biopharmaceuticals Announces Positive Phase 1 Data For Its Adjuvanted S-Trimer Covid-19 Vaccine Candidates

Published: 12/04/2020 08:17 GMT
Dynavax Technologies Corp. (DVAX) - Clover Biopharmaceuticals Announces Positive Phase 1 Data for Its Adjuvanted S-trimer Covid-19 Vaccine Candidates.
Clover - Protein-based Covid-19 S-trimer Vaccine Candidates in Combination With Adjuvants From Either Gsk Or Dynavax Induces Strong Immune Responses.
Clover - Clover’s Vaccine Candidates Both Demonstrated a Favorable Safety and Tolerability Profile.
Clover -adjuvanted S-trimer Covid-19 Vaccine Candidates Induced Strong Neutralizing Immune Responses in 150 Adult, Elderly From Phase 1 Clinical Study.
Clover - Clover’s Vaccine Candidates Have Also Shown Long-term Stability at 2-8 Degree C, Making Them Suitable for Global Distribution.
Clover - Global Phase 2/3 Trial of S-trimer Vaccine Candidate in Combination With Gsk’s Pandemic Adjuvant System is Expected to Begin in Dec 2020.
Clover - Pivotal Phase 2/3 Clinical Trial of Candidate in Combination With Dynavax’s Advanced Cpg 1018 Adjuvant Plus Alum Intended to Start in H1 2021.
Clover - No Serious Adverse Events Related to the Vaccine Candidates Studied Were Reported.
Clover - Strong Th1 Cell-mediated Immune Responses Were Also Observed for the Vaccine Candidates With Either Adjuvant.
Revenue is expected to be $38.58 Million
Adjusted EPS is expected to be -$0.13

Next Quarter Revenue Guidance is expected to be $44.4 Million
Next Quarter EPS Guidance is expected to be -$0.11

More details on our Analysts Page.